Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引:0
|
作者
Armstrong, April W. [1 ]
Soliman, Ahmed M. [2 ]
Gisondi, Paolo [3 ]
Fang, Siran [2 ]
Patel, Manish [2 ]
Strober, Bruce [4 ,5 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Dermatol, 1450 San Pablo St 5400, Los Angeles, CA 90033 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy
[4] Yale Univ, Dept Dermatol, New Haven, CT USA
[5] Cent Connecticut Dermatol, Cromwell, CT USA
关键词
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab; ADALIMUMAB;
D O I
10.1007/s13555-024-01293-y
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionDespite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical effectiveness of risankizumab and deucravacitinib in patients with moderate-to-severe PsO.MethodsThis placebo-anchored matching-adjusted indirect comparison (MAIC) analysis utilized data from UltIMMa-1/2 risankizumab and POETYK PSO-1/2 deucravacitinib trials. Individual patient data from UltiMMA-1/2 were weighted via propensity score to match POETYK PSO-1/2 published summary data. Rate differences between risankizumab and deucravacitinib were assessed for Psoriasis Area and Severity Index (PASI) 75/90/100, the Static Physician Global Assessment (sPGA = 0 or 0/1), and the Dermatology Life Quality Index (DLQI) 0/1.ResultsAt 16 weeks, risankizumab-treated patients demonstrated statistically significantly higher rates of skin clearance and greater improvement in quality of life (QoL) compared to those treated with deucravacitinib. Across all outcomes, risankizumab demonstrated a lower number needed to treat compared to deucravacitinib. Limitations are potential bias due to unobserved/unmeasurable differences and limited generalizability of the results.ConclusionsThis indirect comparison demonstrates that risankizumab has higher rates of skin clearance and greater improvements in QoL than deucravacitinib. This study will help inform healthcare providers in their treatment and management strategy of PsO.
引用
收藏
页码:3071 / 3081
页数:11
相关论文
共 50 条
  • [41] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
  • [42] Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
    Heydendael, VMR
    Spuls, PI
    Opmeer, BC
    de Borgie, CAJM
    Reitsma, JB
    Goldschmidt, WFM
    Bossuyt, PMM
    Bos, JD
    de Rie, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 658 - 665
  • [43] Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
    Hannah A. Blair
    Drugs, 2020, 80 : 1505 - 1505
  • [44] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Cabaleiro, Teresa
    Solano-Lopez, Guillermo
    Marquez, Beatriz
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
  • [45] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
  • [46] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [47] Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice
    Saure, Daniel
    Wilhelm, Stefan
    Dossenbach, Martin
    Thaci, Diamant
    Smith, Saxon D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB82 - AB82
  • [48] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
    Gordon, K. B.
    Lebwohl, M.
    Papp, K. A.
    Bachelez, H.
    Wu, J. J.
    Langley, R. G.
    Blauvelt, A.
    Kaplan, B.
    Shah, M.
    Zhao, Y.
    Sinvhal, R.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
  • [49] Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
    Mease, Philip J.
    Warren, Richard B.
    Nash, Peter
    Grouin, Jean-Marie
    Lyris, Nikos
    Willems, Damon
    Taieb, Vanessa
    Eells, Jason
    Mcinnes, Iain B.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1403 - 1412
  • [50] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Crowley, Jeffrey J.
    Langley, Richard G.
    Gordon, Kenneth B.
    Pinter, Andreas
    Ferris, Laura K.
    Rubant, Simone
    Photowala, Huzefa
    Xue, Zhenyi
    Wu, Tianshuang
    Zhan, Tianyu
    Beeck, Stefan
    Shah, Megha
    Warren, Richard B.
    DERMATOLOGY AND THERAPY, 2022, 12 (02) : 561 - 575